Last reviewed · How we verify
Piperacillin Sodium and Sulbactam Sodium
Piperacillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while sulbactam inhibits bacterial β-lactamases to prevent antibiotic degradation.
Piperacillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while sulbactam inhibits bacterial β-lactamases to prevent antibiotic degradation. Used for Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections, Polymicrobial infections and infections caused by β-lactamase-producing bacteria.
At a glance
| Generic name | Piperacillin Sodium and Sulbactam Sodium |
|---|---|
| Also known as | xin te mie, te mie jun, xin ke jun |
| Sponsor | Xiangbei Welman Pharmaceutical Co., Ltd |
| Drug class | β-lactam antibiotic with β-lactamase inhibitor |
| Target | Penicillin-binding proteins; bacterial β-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is a broad-spectrum β-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Sulbactam is a β-lactamase inhibitor that protects piperacillin from enzymatic degradation by resistant bacteria, extending the spectrum of activity against β-lactamase-producing organisms. Together, this combination provides enhanced coverage against gram-positive, gram-negative, and anaerobic bacteria.
Approved indications
- Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections
- Polymicrobial infections including those with β-lactamase-producing organisms
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Phlebitis at injection site
- Hypersensitivity reactions
Key clinical trials
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia (PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Safety and Efficacy of Vancomycin Plus Beta-lactams
- Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection (PHASE4)
- Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: